

## Eurofins Medinet Shanghai Central Laboratory Ready for Operation

Today, more and more pharmaceutical companies choose to conduct clinical trials in China. The availability of a large patient pool with a large number of treatment naïve patients and lower trial costs in comparison to USA and Europe are the key drivers for this development. In addition, China is expected to become the world's 5<sup>th</sup> largest local market by 2010, and the 3<sup>rd</sup> largest market by 2020.

In our ongoing commitment to adapt to emerging trends in the pharmaceutical industry, Eurofins Medinet has established a new dedicated Central Laboratory in Suzhou, China. Located near the Yangtze River, Suzhou is home to many high-tech and pharmaceutical enterprises. The facility's proximity to the Shanghai Hongqiao domestic airport ensures a close management of transportation and maintenance of specimen integrity. The newly built facility is accommodating the growth of clinical trials being conducted in China, thereby meeting the special (regulatory) requirements the industry is facing.

"We are excited to be able to facilitate our customers to conduct clinical trials in China" says Robert Willis, Vice President International Laboratory Development. "Complementing the foundation of our Eurofins Medinet facility in Singapore in 2007, we aspire to offer the most appropriate and highest quality central laboratory services in the Asia-Pacific region."

Due to the Chinese export regulations it is pivotal to perform central laboratory testing within Chinese territory. The Eurofins Medinet local laboratory not only offers a

full range of safety parameters but extends its offering by adding a diversity of specialized testing like HPLC and ELISA. Eurofins Medinet Shanghai will support over 80 investigator sites in 8 cities from multiple studies throughout 2008.

The Shanghai facility will operate to the same procedures and quality standards as already established and proven in the other Eurofins Medinet owned facilities. It is planned that the Shanghai facility will achieve NGSP Level 1 accreditation by June 2008 and CAP accreditation in 2009.

The facility in Shanghai extends the current Eurofins Medinet network of central laboratories with owned facilities in the USA, Netherlands, France, Singapore, and standardized partners in South Africa, India, Japan, Australia, Israel, Brazil and Argentina.



*Eurofins Medinet, Suzhou New District, Suzhou China*


## Development of Drug Eluting Stents

Angioplasty is the mechanical widening of a narrowed or totally-obstructed blood vessel. These obstructions are often caused by atherosclerosis. At first, angioplastic balloons were used to widen coronary arteries. Unfortunately, a small percentage of arteries collapsed immediately after the balloon was deflated. Secondly, a substantial portion of arteries began to close up again, a process called restenosis. Restenosis proved to be the body's response to the 'controlled injury' of angioplasty, similar to a scar forming over an injury, rather than a recurrence of coronary artery disease.

In the 1980's and 90s, metal devices called 'stents' were developed to assist cardiologists to overcome the balloon angioplasty related issues. These metal mesh-like tubes eliminated many of the complications of abrupt artery collapse, but restenosis persisted. Although the restenosis occurrence improved to about 25% of the cases, bare metal stents still experienced reblocking, necessitating a new surgical procedure typically at six-months.

In order to further reduce the process of restenosis after angioplasty, the next generation stents consist of a regular metal

stent that is coated with a drug that is known to interrupt the biological processes that cause restenosis. In the clinical data gathered so far, these so called drug-eluting stents appear to reduce restenosis to the single digits. There are three major components to a drug-eluting stent:



- Type of stent that carries the drug coating
- Method by which the drug is delivered/eluted by the coating to the arterial wall
- The drug itself - how does it act in the human body to prevent restenosis?

The Eurofins Medinet Denver laboratory provides a complete range of innovative capabilities to support the development of drug eluting stents. To read the whole article and for other interesting Eurofins Medinet white papers, please visit our website at [www.eurofinsmedinet.com/downloads](http://www.eurofinsmedinet.com/downloads)

## Mark your meeting calendar and visit us at the following conferences

### Bioanalysis in Clinical Research

**20-21 February 2008**  
Olympia Conference Centre,  
London, UK

### 17th Annual Partnerships with CRO's

**14-16 April 2008**  
Mandalay Bay, Las Vegas, USA  
Booth # 410

### 18th ECCMID European Congress of Clinical Microbiology and Infectious Diseases

**19-22 April 2008**  
Barcelona Spain  
Booth # 619

### 4th Annual PEGS Summit

**28-29 April 2008**  
Intercontinental Hotel, Boston,  
Massachusetts, USA

### 9th Annual Meeting for NARSA

**3-4 March 2008**  
Hyatt Regency Reston, VA,  
USA (Hosting Meeting)

If you have any questions or suggestions, please feel free to contact us via [info@eurofinsmedinet.com](mailto:info@eurofinsmedinet.com) or get in touch with your representative.



### Eurofins Medinet

[info@eurofinsmedinet.com](mailto:info@eurofinsmedinet.com)  
[www.eurofinsmedinet.com](http://www.eurofinsmedinet.com)

**Breda**  
**Paris**  
**Washington DC**  
**Denver**  
**Singapore**  
**Shanghai**

tel +31 (0)76 572 72 72  
tel +33 (0)1 3054 6000  
tel +1 866 324 8691  
tel +1 720 859 4190  
tel +65 6562 3858  
tel +85 512 6680 1266



**eurofins**

| **Medinet**